AngioDynamics Company Profile (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) posted its earnings results on Tuesday, July, 18th. The company reported $0.19 EPS for the quarter, beating the Zacks' consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million for the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The company's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.19 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 3rd 2017. View Earnings Estimates for AngioDynamics.

AngioDynamics updated its FY18 earnings guidance on Tuesday, July, 18th. The company provided earnings per share (EPS) guidance of $0.64-0.68 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.68. The company issued revenue guidance of $352-359 million, compared to the consensus revenue estimate of $357.75 million.

5 analysts have issued twelve-month target prices for AngioDynamics' stock. Their forecasts range from $16.00 to $21.00. On average, they anticipate AngioDynamics' share price to reach $18.40 in the next year. View Analyst Ratings for AngioDynamics.

Here are some recent quotes from research analysts about AngioDynamics stock:

• 1. According to Zacks Investment Research, "AngioDynamics reported a mixed fourth quarter of fiscal 2017, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. The year-over-year decline at the company’s Peripheral Vascular, Vascular Access and Oncology & Surgery business segments marred revenues. Furthermore, the company expects earnings to fall sequentially in FY18. Lackluster performance by the oncology segment was primarily due to market withdrawal of the company’s flagship Acculis Microwave Tissue Ablation System, which also marred international sales. AngioDynamics has a high outstanding debt level at the end of the fourth quarter. This is likely to impose certain operating and financial restrictions, limiting the company’s core business strategies. Over the last one year, AngioDynamics has underperformed the broader industry in terms of price. However, growth in the core Angiographic Catheter business holds promise." (7/20/2017)
• 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)

Some companies that are related to AngioDynamics include Amarin Corporation PLC (AMRN), The Ensign Group (ENSG), Aimmune Therapeutics (AIMT), OraSure Technologies (OSUR), Cardiovascular Systems (CSII), Quality Systems (QSII), Community Health Systems (CYH), K2M Group Holdings (KTWO), Surgery Partners (SGRY), Esperion Therapeutics (ESPR), Insmed (INSM), Forward Pharma A/S (FWP), BioTelemetry (BEAT), Kindred Healthcare (KND), Mazor Robotics (MZOR), Immunomedics (IMMU), Cellectis S.A. (CLLS) and Synergy Pharmaceuticals (SGYP).

AngioDynamics' management team includes the folowing people:

• Howard W. Donnelly, Independent Chairman of the Board
• James C. Clemmer, President, Chief Executive Officer, Director
• Michael Greiner, Chief Financial Officer, Executive Vice President
• Gary Barrett, Senior Vice President,Quality and Regulatory Affairs
• Ben Davis, Senior Vice President, Business Development
• Barbara Kucharczyk, Senior Vice President-Global Operations
• Stephen A. Trowbridge, Senior Vice President, General Counsel
• Eileen O'Shea Auen, Director
• Jan Stern Reed, Director
• David F. Burgstahler, Independent Director

AngioDynamics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (2.04%), Fenimore Asset Management Inc. (1.57%), Bank of Montreal Can (0.71%), First Quadrant L P CA (0.31%), Capital One National Association (0.25%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler and Stephen A Trowbridge. View Institutional Ownership Trends for AngioDynamics.

AngioDynamics' stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Fenimore Asset Management Inc., GW&K Investment Management LLC, First Quadrant L P CA, Capital One National Association, State of Alaska Department of Revenue and Louisiana State Employees Retirement System. View Insider Buying and Selling for AngioDynamics.

Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AngioDynamics stock can currently be purchased for approximately $15.75.